The NTU JO-SMART Study

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorNational Taiwan University Hospital

About this trial

This study recruits patients with coexisting obesity and knee osteoarthritis (KOA) to implement the NTU-JO Smart Program, an innovative intervention integrating AI-assisted community-based exercise with continuous glucose monitoring (CGM). The primary objective is to investigate whether this intervention can improve glycemic control in this comorbid population. Other outcome measures include the risk of total knee arthroplasty (TKA), body weight changes, pain intensity scores, bone mineral density (BMD), cognitive function, as well as the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and Patient-Reported Outcomes Measurement Information System (PROMIS) scores, which reflect the patients' overall functional status. The project also sought to explore the long-term association of the NTU-JO Smart Program with the development of type 2 diabetes (T2D) and major renal events, thereby facilitating patient-centered early treatment.

Eligibility criteria

Qualifiers

Age: 18 to 75 years.

Obesity status: body mass index (BMI) ≥ 27 kg/m², consistent with the obesity definition defined by the Health Promotion Administration, Ministry of Health and Welfare, Taiwan.

Diagnosis of KOA in at least one knee according to the American College of Rheumatology (ACR) criteria, with a Kellgren-Lawrence (KL) grade of 1, 2, or 3.

Symptomatic disease: defined as a WOMAC pain subscale score (range 0-20) greater than 4 at screening.

Disqualifiers

KL grade 4 KOA in either knee.

Diagnosis of inflammatory arthritis, such as rheumatoid arthritis or psoriatic arthritis.

Knee arthroscopy within the past 3 months or previous surgical history of TKA.

Recent receipt of intra-articular injections (e.g., corticosteroids, hyaluronic acid) within the past 3 months.

Trial design

Treatments tested in this trial

  • NTU-JO Smart Program

Treatment groups

312 Participants
are divided into 2 treatment groups

Sponsors and collaborators

National Taiwan University Hospital

Lead sponsor

National Science and Technology Council, Taiwan

Collaborator